French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...

French drug major Sanofi (SNYNF, SNY) reported third quarter net income attributable to equity holders of the company of 2.82 billion ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted ...

Sanofi is now in “exclusive negotiations ... With the French government saying that it has received assurances from New York City-based CD&R that it will keep Opella’s manufacturing facilities ...

Sanofi has returned with 300 million euros ($326 million) to set up a more permanent radioligand project. The new entity, which will operate under the Orano Med brand, will be focused on ...

Sanofi is deepening its commitment to targeted radiation treatments for cancer with a €300 million equity investment in a new entity pursuing next-generation radioligand therapies. The new ...

PARIS, Oct 11 (Reuters) - Sanofi (SASY.PA), opens new tab has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier ...

POM Investment Strategies LLC acquired a new stake in Sanofi during the second quarter worth approximately $25,000. Register Financial Advisors LLC bought a new position in shares of Sanofi in the ...

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private ...

(RTTNews) - Sanofi (SNYNF) announced it has entered into exclusive negotiations to sell a 50 percent controlling stake in its consumer healthcare business, Opella, to private equity firm CD&R.

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

This newsletter was penned in the company of some mastodon fossils in New York. They say good morning, too. Today, we see an escalating battle between Eli Lilly and compounding pharmacies putting ...